ArticleExperimental hematology & oncology2024

Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion.

Diana Malarikova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.